News / Biotech

Galecto Acquires Damora Therapeutics: A New Focus on Blood Cancer Treatments

Galecto, Inc. (NASDAQ: GLTO) has completed its acquisition of Damora Therapeutics, a privately held biotech firm specializing in treatments for mutant calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPNs). This strategic move, a...

Nov 10, 2025 13:34 Galecto (GLTO) raises $284.9M as Damora deal closes, funding operations into 2029